{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:59Z","timestamp":1790916839559,"version":"4.1.0"},"reference-count":74,"publisher":"Bentham Science Publishers Ltd.","issue":"25","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Heterocyclic compounds remain cornerstones of contemporary\ndrug discovery because their ring-embedded heteroatoms confer adaptable electronics,\nconformational flexibility, and a broad spectrum of biological activities. The skeleton\nstructure of 4-thiazolidinone is present in many cytotoxically active compounds and is\noften used in the design of new antitumor agents. This study aimed to synthesize, characterize,\nand evaluate the anticancer potential of fifteen new (2-imino-4-oxo-1,3-thiazolidin-\n5-yl)acetic acid derivatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Compounds were synthesized using a consistent synthetic route involving a reaction\nbetween a thiourea derivative and maleic anhydride, which formed the thiazolidin-\n4-one ring through cyclization. The compounds were then categorized into three sets\nbased on the attached heterocyclic rings (tryptamine, thiazole, and 1,2,4-triazole). The\nNMR and X-ray analysis followed the synthesis. Apoptotic effects, cell cycle arrest,\nIL-6 suppression, docking, and dynamics simulations were conducted. Preliminary cytotoxic\nactivity was tested on metastatic colorectal cancer (SW620) and human breast adenocarcinoma\n(MDA-MB-231) cell lines using the MTT assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Compounds 5, 6, and 7 demonstrated notable selectivity indexes (4.73, 2.42,\n4.16, respectively) and were further investigated for their mechanisms of action, revealing\npro-apoptotic properties and the ability to induce cell cycle arrest. Additionally, compound\n5 inhibited IL-6 secretion by 76%. in silico studies revealed the formation of an\nenergetically stable complex between compound 5 and the EGFR crystal structure (min\/-\nmax binding affinities of -9.4|-8.0 kcal\/mol, compared to the -7.71 kcal\/mol for the native\nligand).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>This preliminary study provides compelling data on synthesized derivatives,\nbut more advanced testing is needed to assess their therapeutic value fully. Compared\nwith earlier reports on related thiazolidinone scaffolds, the present derivatives exhibit\nimproved potency, clearer selectivity, and mechanistic features consistent with\nEGFR inhibition and cytokine modulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These findings validate (2-imino-4-oxo-1,3-thiazolidin-5-yl)acetic acid as\na privileged core for cytotoxic lead generation and indicate that strategic substitution\nwith either a tryptamine moiety (compound 5) or a 1,2,4-triazole ring (compound 7) is\nparticularly advantageous. These compounds are promising EGFR-targeting anticancer\ncandidates, warranting further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673400295250913044755","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:45:27Z","timestamp":1760528727000},"page":"5268-5296","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synthesis, Cytotoxicity Evaluation, and Molecular Dynamics of 4-Thiazolidinone Derivatives: A Potential Path to EGFR-Targeted Anticancer Therapy"],"prefix":"10.2174","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4830-1473","authenticated-orcid":true,"given":"Tomasz","family":"Szostek","sequence":"first","affiliation":[{"name":"Chair and Department of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3378-4169","authenticated-orcid":true,"given":"Dagmara","family":"Otto-Slusarczyk","sequence":"additional","affiliation":[{"name":"Chair and Department of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1435-5668","authenticated-orcid":true,"given":"Micha\u0142 A.","family":"Dobrowolski","sequence":"additional","affiliation":[{"name":"Facultyof Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2470-6425","authenticated-orcid":true,"given":"Maciej","family":"Wisniewski","sequence":"additional","affiliation":[{"name":"Laboratory of Bioinformaticsand Computational Genomics, Faculty of Mathematics and Information Science, Warsaw, Poland"},{"name":"Laboratory of Functional and Structural Genomics, Center of New Technologies, University of Warsaw, Warsaw,Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6391-7233","authenticated-orcid":true,"given":"Piotr","family":"Roszkowski","sequence":"additional","affiliation":[{"name":"Facultyof Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3083-456X","authenticated-orcid":true,"given":"Daniel","family":"Szulczyk","sequence":"additional","affiliation":[{"name":"Chair and Department of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"Siegel R.L.","year":"2019","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2019. CA Cancer J Clin  2019,69(1),7-34","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","volume":"9","author":"Mattiuzzi C.","year":"2019","unstructured":"Mattiuzzi C.; Lippi G.; Current Cancer Epidemiology. J Epidemiol Glob Health  2019,9(4),217-222","journal-title":"J Epidemiol Glob Health"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/life12010048","volume":"12","author":"Basak D.","year":"2021","unstructured":"Basak D.; Arrighi S.; Darwiche Y.; Deb S.; Comparison of Anticancer drug toxicities: paradigm shift in adverse effect profile. Life  2021,12(1),48","journal-title":"Life"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/jhet.3514","volume":"56","author":"Nirwan S.","year":"2019","unstructured":"Nirwan S.; Chahal V.; Kakkar R.; Thiazolidinones: Synthesis, reactivity, and their biological applications. J Heterocycl Chem  2019,56(4),1239-1253","journal-title":"J Heterocycl Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/1479164118825376","volume":"16","author":"DeFronzo R.A.","year":"2019","unstructured":"DeFronzo R.A.; Inzucchi S.; Abdul-Ghani M.; Nissen S.E.; Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res  2019,16(2),133-143","journal-title":"Diab Vasc Dis Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2165\/00024677-200201060-00006","volume":"1","author":"Wagstaff A.J.","year":"2002","unstructured":"Wagstaff A.J.; Goa K.L.; Spotlight on rosiglitazone in the management of type 2 diabetes mellitus. Treat Endocrinol  2002,1(6),411-414","journal-title":"Treat Endocrinol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1592\/phco.28.5.646","volume":"28","author":"Ramirez M.A.","year":"2008","unstructured":"Ramirez M.A.; Borja N.L.; Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy  2008,28(5),646-655","journal-title":"Pharmacotherapy"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2165\/00003495-198600314-00006","volume":"31","author":"McLoughlin C.","year":"1986","unstructured":"McLoughlin C.; Diuretic drugs. Drugs  1986,31(Suppl 4(2)),50-51","journal-title":"Drugs"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/BF00171088","volume":"346","author":"Fischer W.","year":"1992","unstructured":"Fischer W.; Bodewei R.; Satzinger G.; Anticonvulsant and sodium channel blocking effects of ralitoline in different screening models. Naunyn Schmiedebergs Arch Pharmacol  1992,346(4),442-452","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40265-021-01523-z","volume":"81","author":"Markham A.","year":"2021","unstructured":"Markham A.; Ponesimod: First Approval. Drugs  2021,81(8),957-962","journal-title":"Drugs"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s11030-020-10087-1","volume":"25","author":"T\u00fcre A.","year":"2021","unstructured":"T\u00fcre A.; Erg\u00fcl M.; Erg\u00fcl M.; Altun A.; K\u00fc\u00e7\u00fckg\u00fczel \u0130.; Design, synthesis, and anticancer activity of novel 4-thiazolidinone-phenylaminopyrimidine hybrids. Mol Divers  2021,25(2),1025-1050","journal-title":"Mol Divers"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cbi.2016.12.008","volume":"262","author":"Szychowski K.A.","year":"2017","unstructured":"Szychowski K.A.; Leja M.L.; Kaminskyy D.V.; Binduga U.E.; Pinyazhko O.R.; Lesyk R.B.; Gmi\u0144ski J.; Study of novel anticancer 4-thiazolidinone derivatives. Chem Biol Interact  2017,262,46-56","journal-title":"Chem Biol Interact"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"106496","DOI":"10.1016\/j.bioorg.2023.106496","volume":"135","author":"Amin N.H.","year":"2023","unstructured":"Amin N.H.; El-Saadi M.T.; Abdel-Fattah M.M.; Mohammed A.A.; Said E.G.; Development of certain aminoquinazoline scaffolds as potential multitarget anticancer agents with apoptotic and anti-proliferative effects: Design, synthesis and biological evaluation. Bioorg Chem  2023,135,106496","journal-title":"Bioorg Chem"},{"key":"ref=14","first-page":"353","author":"Nossier E.","year":"2015","unstructured":"Nossier E.; El-Hallouty S.; Zaki E.; Synthesis, anticancer evaluation and molecular modeling of some substituted thiazolidinonyl and thiazolyl pyrazole derivatives. Int J Pharm Pharm Sci  2015,353-359","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1021\/acs.jmedchem.3c01802","volume":"67","author":"Chen L.","year":"2024","unstructured":"Chen L.; Mao W.; Ren C.; Li J.; Zhang J.; Comprehensive insights that targeting pim for cancer therapy: prospects and obstacles. J Med Chem  2024,67(1),38-64","journal-title":"J Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jbm.a.10481","volume":"65A","author":"Konno T.","year":"2003","unstructured":"Konno T.; Watanabe J.; Ishihara K.; Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers. J Biomed Mater Res A  2003,65A(2),209-214","journal-title":"J Biomed Mater Res A"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/biom15020262","volume":"15","author":"Yudaev P.","year":"2025","unstructured":"Yudaev P.; Tupikov A.; Chistyakov E.; Organocyclophosphazenes and materials based on them for pharmaceuticals and biomedicine. Biomolecules  2025,15(2),262","journal-title":"Biomolecules"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"19857","DOI":"10.1039\/c6ra24662a","volume":"7","author":"Abbot V.","year":"2017","unstructured":"Abbot V.; Sharma P.; Dhiman S.; Noolvi M. N.; Patel H. M.; Bhardwaj V.; Small hybrid heteroaromatics: resourceful biological tools in cancer research. RSC Advances  2017,7,19857-19887","journal-title":"RSC Advances"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1038\/s41598-024-54021-z","volume":"14","author":"Gul S.","year":"2024","unstructured":"Gul S.; Jan F.; Alam A.; Shakoor A.; Khan A.; AlAsmari A.F.; Alasmari F.; Khan M.; Bo L.; Synthesis, molecular docking and DFT analysis of novel bis-Schiff base derivatives with thiobarbituric acid for \u03b1-glucosidase inhibition assessment. Sci Rep  2024,14(1),3419","journal-title":"Sci Rep"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1134\/S1068162024050030","volume":"50","author":"Gul S.","year":"2024","unstructured":"Gul S.; Maab S.; Rafiq H.; Alam A.; Rehman M.U.; Assad M.; AlAsmari A.F.; Alasmari F.; Ibrahim M.; Khan M.; Exploring bis-Schiff Bases with Thiobarbiturate Scaffold: In Vitro Urease Inhibition, Antioxidant Properties, and In Silico Studies. Russ J Bioorganic Chem  2024,50(5),1627-1638","journal-title":"Russ J Bioorganic Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4155\/fmc-2023-0267","volume":"16","author":"Shakoor A.","year":"2024","unstructured":"Shakoor A.; Alam A.; Jan F.; Khan M.; Ali M.; Ullah S.; Khan A.; AlAsmari A.F.; Alasmari F.; Al-Ghafri A.; Al-Harrasi A.; Novel benzimidazole derivatives as effective inhibitors of prolyl oligopeptidase: synthesis, in vitro and in silico analysis. Future Med Chem  2024,16(1),43-58","journal-title":"Future Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e202401904","DOI":"10.1002\/slct.202401904","volume":"9","author":"Shakoor A.","year":"2024","unstructured":"Shakoor A.; Alam A.; Ali M.; Ullah S.; Halim S.A.; Rehman M.U.; AlAsmari A.F.; Alasmari F.; Khan A.; Khan M.; Al-Harrasi A.; Synthesis of novel benzimidazole analogs for neurodegenerative diseases by targeting prolyl oligopeptidase. ChemistrySelect  2024,9(34),e202401904","journal-title":"ChemistrySelect"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e202402096","DOI":"10.1002\/cbdv.202402096","volume":"22","author":"Shakoor A.","year":"2025","unstructured":"Shakoor A.; Jan F.; Rahman S.; Ali M.; Ibrahim M.; Khan H.; Alam A.; Khan A.; Ali A.; Al-Olayan E.; Abukhadra M.R.; Al-Harrasi A.; Khan M.; Synthesis, urease inhibitory activity, molecular docking, dynamics, mmgbsa and dft studies of hydrazone-schiff bases bearing benzimidazole scaffold. Chem Biodivers  2025,22(3),e202402096","journal-title":"Chem Biodivers"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"25717","DOI":"10.1039\/D3RA03841F","volume":"13","author":"Ahmad S.","year":"2023","unstructured":"Ahmad S.; Khan M.; Alam A.; Ajmal A.; Wadood A.; Khan A.; AlAsmari A.F.; Alharbi M.; Alshammari A.; Shakoor A.; Novel flurbiprofen clubbed oxadiazole derivatives as potential urease inhibitors and their molecular docking study. RSC Advances  2023,13(37),25717-25728","journal-title":"RSC Advances"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.2147\/DDDT.S521541","volume":"19","author":"Al-Saleem M.","year":"2025","unstructured":"Al-Saleem M.; Mohamed Ahmed M.; Riyadh S.; Alruwaili A.; Zaki M.; Gomha S.; Synthesis, molecular characterization, and antimicrobial evaluation of hydrazones derived from 2-hydrazinobenzimidazole. Drug Des Devel Ther  2025,19,4437-4456","journal-title":"Drug Des Devel Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1016\/j.bmcl.2015.06.070","volume":"25","author":"Salikov R.F.","year":"2015","unstructured":"Salikov R.F.; Belyy A.Yu.; Khusnutdinova N.S.; Vakhitova Y.; Synthesis and cytotoxic properties of tryptamine derivatives. Bioorg Med Chem Lett  2015,25(17),3597-3600","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3390\/molecules26030683","volume":"26","author":"Simonetti G.","year":"2021","unstructured":"Simonetti G.; Boga C.; Durante J.; Micheletti G.; Telese D.; Caruana P.; Ghelli Luserna di Ror\u00e0 A.; Mantellini F.; Bruno S.; Martinelli G.; Calonghi N.; Synthesis of novel tryptamine derivatives and their biological activity as antitumor agents. Molecules  2021,26(3),683","journal-title":"Molecules"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"112652","DOI":"10.1016\/j.ejmech.2020.112652","volume":"205","author":"Aggarwal R.","year":"2020","unstructured":"Aggarwal R.; Sumran G.; An insight on medicinal attributes of 1,2,4-triazoles. Eur J Med Chem  2020,205,112652","journal-title":"Eur J Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1634\/theoncologist.2011-0287","volume":"16","author":"Cohen M.H.","year":"2011","unstructured":"Cohen M.H.; Johnson J.R.; Justice R.; Pazdur R.; Approval summary: letrozole (Femara tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval. Oncologist  2011,16(12),1762-1770","journal-title":"Oncologist"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"116578","DOI":"10.1016\/j.ejmech.2024.116578","volume":"275","author":"Guan Q.","year":"2024","unstructured":"Guan Q.; Gao Z.; Chen Y.; Guo C.; Chen Y.; Sun H.; Structural modification strategies of triazoles in anticancer drug development. Eur J Med Chem  2024,275,116578","journal-title":"Eur J Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"640","DOI":"10.2174\/1389557517666171123211321","volume":"18","author":"Jain S.","year":"2018","unstructured":"Jain S.; Pattnaik S.; Pathak K.; Kumar S.; Pathak D.; Jain S.; Vaidya A.; Anticancer potential of thiazole derivatives: a retrospective review. Mini Rev Med Chem  2018,18(8),640-655","journal-title":"Mini Rev Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.ejmech.2017.12.040","volume":"144","author":"de Santana T.I.","year":"2018","unstructured":"de Santana T.I.; Barbosa M.O.; Gomes P.A.T.M.; da Cruz A.C.N.; da Silva T.G.; Leite A.C.L.; Synthesis, anticancer activity and mechanism of action of new thiazole derivatives. Eur J Med Chem  2018,144,874-886","journal-title":"Eur J Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.3390\/molecules29102200","volume":"29","author":"J\u0119drzejczyk M.","year":"2024","unstructured":"J\u0119drzejczyk M.; Morabito B.; \u017by\u017cy\u0144ska-Granica B.; Struga M.; Janczak J.; Aminpour M.; Tuszynski J.A.; Huczy\u0144ski A.; Novel combretastatin a-4 analogs\u2014design, synthesis, and antiproliferative and anti-tubulin activity. Molecules  2024,29(10),2200","journal-title":"Molecules"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.3390\/ijms25084148","volume":"25","author":"Jele\u0144 M.","year":"2024","unstructured":"Jele\u0144 M.; Otto-\u015alusarczyk D.; Morak-M\u0142odawska B.; Struga M.; Novel tetracyclic azaphenothiazines with the quinoline ring as new anticancer and antibacterial derivatives of chlorpromazine. Int J Mol Sci  2024,25(8),4148","journal-title":"Int J Mol Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/molecules26020323","volume":"26","author":"Szulczyk D.","year":"2021","unstructured":"Szulczyk D.; Bielenica A.; Roszkowski P.; Dobrowolski M.A.; Olejarz W.; Kmiecik S.; Podsiad M.; Struga M.; Synthetic transition from thiourea-based compounds to tetrazole derivatives: Structure and biological evaluation of synthesized new N-(furan-2-ylmethyl)-1H-tetrazol-5- amine derivatives. Molecules  2021,26(2),323","journal-title":"Molecules"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.3390\/ijms23126600","volume":"23","author":"Szostek T.","year":"2022","unstructured":"Szostek T.; Szulczyk D.; Szyma\u0144ska-Majchrzak J.; Koli\u0144ski M.; Kmiecik S.; Otto-\u015alusarczyk D.; Zawodnik A.; Rajkowska E.; Chaniewicz K.; Struga M.; Roszkowski P.; Design and synthesis of menthol and thymol derived ciprofloxacin: influence of structural modifications on the antibacterial activity and anticancer properties. Int J Mol Sci  2022,23(12),6600","journal-title":"Int J Mol Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1107\/S0021889808042726","volume":"42","author":"Dolomanov O.V.","year":"2009","unstructured":"Dolomanov O.V.; Bourhis L.J.; Gildea R.J.; Howard J.A.K.; Puschmann H.; OLEX2 : a complete structure solution, refinement and analysis program. J Appl Cryst  2009,42(2),339-341","journal-title":"J Appl Cryst"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1021\/ci300604z","volume":"53","author":"Koes D.R.","year":"2013","unstructured":"Koes D.R.; Baumgartner M.P.; Camacho C.J.; Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. J Chem Inf Model  2013,53(8),1893-1904","journal-title":"J Chem Inf Model"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e1005659","DOI":"10.1371\/journal.pcbi.1005659","volume":"13","author":"Eastman P.","year":"2017","unstructured":"Eastman P.; Swails J.; Chodera J.D.; McGibbon R.T.; Zhao Y.; Beauchamp K.A.; Wang L.P.; Simmonett A.C.; Harrigan M.P.; Stern C.D.; Wiewiora R.P.; Brooks B.R.; Pande V.S.; OpenMM 7: Rapid development of high performance algorithms for molecular dynamics. PLOS Comput Biol  2017,13(7),e1005659","journal-title":"PLOS Comput Biol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1093\/nar\/gkg543","volume":"31","author":"Eswar N.","year":"2003","unstructured":"Eswar N.; John B.; Mirkovic N.; Fiser A.; Ilyin V.A.; Pieper U.; Stuart A.C.; Marti-Renom M.A.; Madhusudhan M.S.; Yerkovich B.; Sali A.; Tools for comparative protein structure modeling and analysis. Nucleic Acids Res  2003,31(13),3375-3380","journal-title":"Nucleic Acids Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"Maier J.A.","year":"2015","unstructured":"Maier J.A.; Martinez C.; Kasavajhala K.; Wickstrom L.; Hauser K.E.; Simmerling C.; Ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput  2015,11(8),3696-3713","journal-title":"J Chem Theory Comput"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"Roe D.R.","year":"2013","unstructured":"Roe D.R.; Cheatham T.E.; PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput  2013,9(7),3084-3095","journal-title":"J Chem Theory Comput"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"Vald\u00e9s-Tresanco M.S.","year":"2021","unstructured":"Vald\u00e9s-Tresanco M.S.; Vald\u00e9s-Tresanco M.E.; Valiente P.A.; Moreno E.; Gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Comput  2021,17(10),6281-6291","journal-title":"J Chem Theory Comput"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1021\/ct300341d","volume":"8","author":"Wang J.","year":"2012","unstructured":"Wang J.; Cai Q.; Xiang Y.; Luo R.; Reducing grid-dependence in finite-difference Poisson-Boltzmann calculations. J Chem Theory Comput  2012,8(8),2741-2751","journal-title":"J Chem Theory Comput"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/prot.20033","volume":"55","author":"Onufriev A.","year":"2004","unstructured":"Onufriev A.; Bashford D.; Case D.A.; Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins  2004,55(2),383-394","journal-title":"Proteins"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"btae416","DOI":"10.1093\/bioinformatics\/btae416","volume":"40","author":"Swanson K.","year":"2024","unstructured":"Swanson K.; Walther P.; Leitz J.; Mukherjee S.; Wu J.C.; Shivnaraine R.V.; Zou J.; ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. Bioinformatics  2024,40(7),btae416","journal-title":"Bioinformatics"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"51780","DOI":"10.1039\/C4RA07840C","volume":"4","author":"Pankova A.S.","year":"2014","unstructured":"Pankova A.S.; Samartsev M.A.; Shulgin I.A.; Golubev P.R.; Avdontceva M.S.; Kuznetsov M.A.; Synthesis of thiazolidines via regioselective addition of unsymmetric thioureas to maleic acid derivatives. RSC Advances  2014,4(93),51780-51786","journal-title":"RSC Advances"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3762\/BJOC.12.251","volume":"12","author":"Pankova A. S.","year":"2016","unstructured":"Pankova A. S.; Golubev P. R.; Khlebnikov A. F.; Ivanov A. Y.; Kuznetsov M. A.; Thiazol-4-one derivatives from the reaction of monosubstituted thioureas with maleimides: structures and factors determining the selectivity and tautomeric equilibrium in solution. Beilstein J Org Chem  2016,12,2563-2569","journal-title":"Beilstein J Org Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e02330","DOI":"10.1016\/j.heliyon.2019.e02330","volume":"5","author":"Achoui N.","year":"2019","unstructured":"Achoui N.; Zaioua K.; Hammout\u00e8ne D.; Kolli-Nedjar B.; Akacem Y.; Interaction of thiourea and urea with maleimide: comparative theoretical DFT study. Heliyon  2019,5(9),e02330","journal-title":"Heliyon"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-0716-2736-5_1","volume":"2579","author":"Wang Z.","year":"2022","unstructured":"Wang Z.; Cell cycle progression and synchronization: an overview. Methods Mol Biol  2022,2579,3-23","journal-title":"Methods Mol Biol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"10875","DOI":"10.1007\/s11033-022-07788-1","volume":"49","author":"Jamasbi E.","year":"2022","unstructured":"Jamasbi E.; Hamelian M.; Hossain M.A.; Varmira K.; The cell cycle, cancer development and therapy. Mol Biol Rep  2022,49(11),10875-10883","journal-title":"Mol Biol Rep"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/35077213","volume":"411","author":"Evan G.I.","year":"2001","unstructured":"Evan G.I.; Vousden K.H.; Proliferation, cell cycle and apoptosis in cancer. Nature  2001,411(6835),342-348","journal-title":"Nature"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"111776","DOI":"10.1016\/j.mrfmmm.2022.111776","volume":"824","author":"Vakili-Samiani S.","year":"2022","unstructured":"Vakili-Samiani S.; Khanghah O.J.; Gholipour E.; Najafi F.; Zeinalzadeh E.; Samadi P.; Sarvarian P.; Pourvahdani S.; Kelaye S.K.; Hamblin M.R.; Feizi A.A.H.; Cell cycle involvement in cancer therapy; WEE1 kinase, a potential target as therapeutic strategy. Mutat Res  2022,824,111776","journal-title":"Mutat Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"e20190347","DOI":"10.1084\/jem.20190347","volume":"217","author":"Kang S.","year":"2020","unstructured":"Kang S.; Narazaki M.; Metwally H.; Kishimoto T.; Historical overview of the interleukin-6 family cytokine. J Exp Med  2020,217(5),e20190347","journal-title":"J Exp Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"Johnson D.E.","year":"2018","unstructured":"Johnson D.E.; O\u2019Keefe R.A.; Grandis J.R.; Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol  2018,15(4),234-248","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jss.2007.04.022","volume":"147","author":"Moran D.M.","year":"2008","unstructured":"Moran D.M.; Mattocks M.A.; Cahill P.A.; Koniaris L.G.; McKillop I.H.; Interleukin-6 mediates G(0)\/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J Surg Res  2008,147(1),23-33","journal-title":"J Surg Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/S13277-016-5098-7","volume":"37","author":"Kumari N.","year":"2016","unstructured":"Kumari N.; Dwarakanath B. S.; Das A.; Bhatt A. N.; Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol  2016,37(9),11553-11572","journal-title":"Tumour Biol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1038\/s41598-019-38574-y","volume":"9","author":"Hossein-Nejad-Ariani H.","year":"2019","unstructured":"Hossein-Nejad-Ariani H.; Althagafi E.; Kaur K.; Small peptide ligands for targeting egfr in triple negative breast cancer cells. Sci Rep  2019,9(1),2723","journal-title":"Sci Rep"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.3390\/ijms25053066","volume":"25","author":"Abrahams B.","year":"2024","unstructured":"Abrahams B.; Gerber A.; Hiss D.C.; Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro . Int J Mol Sci  2024,25(5),3066","journal-title":"Int J Mol Sci"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","volume":"277","author":"Stamos J.","year":"2002","unstructured":"Stamos J.; Sliwkowski M.X.; Eigenbrot C.; Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem  2002,277,46265-46272","journal-title":"J Biol Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2210\/pdb2ito\/pdb","volume":"11","author":"Yun C.-H.","year":"2007","unstructured":"Yun C.-H.; Boggon T.J.; Li Y.; Woo S.; Greulich H.; Meyerson M.; Eck M.J.; Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell  2007,11,217-227","journal-title":"Cancer Cell"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.2210\/pdb4I23\/pdb","author":"Gajiwala K.S.","year":"2013","unstructured":"Gajiwala K.S.; Feng J.; Ferre R.; Ryan K.; Brodsky O.; Stewart A.; Crystal structure of the wild-type EGFR kinase domain in complex with dacomitinib (soaked). Protein Data Bank  2013","journal-title":"Protein Data Bank"},{"key":"ref=63","doi-asserted-by":"publisher","DOI":"10.2210\/pdb4LL0\/pdb","author":"Yun C.H.","year":"2013","unstructured":"Yun C.H.; Eck M.J.; EGFR L858R\/T790M in complex with PD168393. Protein Data Bank  2013","journal-title":"Protein Data Bank"},{"key":"ref=64","doi-asserted-by":"publisher","DOI":"10.2210\/pdb7AEM\/pdb","author":"Hargreaves D.","year":"2021","unstructured":"Hargreaves D.; Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series. Protein Data Bank  2021","journal-title":"Protein Data Bank"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1021\/acs.jmedchem.6b00280","volume":"59","author":"Ugolini A.","year":"2016","unstructured":"Ugolini A.; Kenigsberg M.; Rak A.; Vall\u00e9e F.; Houtmann J.; Lowinski M.; Capdevila C.; Khider J.; Albert E.; Martinet N.; Nemecek C.; Grapinet S.; Bacqu\u00e9 E.; Roesner M.; Delaisi C.; Calvet L.; Bonche F.; Semiond D.; Egile C.; Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844). J Med Chem  2016,59(15),7066-7074","journal-title":"J Med Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00280-005-0123-3","volume":"57","author":"Balin-Gauthier D.","year":"2006","unstructured":"Balin-Gauthier D.; Delord J.P.; Rochaix P.; Mallard V.; Thomas F.; Hennebelle I.; Bugat R.; Canal P.; Allal C.; In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol  2006,57(6),709-718","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s11427-018-9342-2","volume":"61","author":"Zhong F.","year":"2018","unstructured":"Zhong F.; Xing J.; Li X.; Liu X.; Fu Z.; Xiong Z.; Lu D.; Wu X.; Zhao J.; Tan X.; Li F.; Luo X.; Li Z.; Chen K.; Zheng M.; Jiang H.; Artificial intelligence in drug design. Sci China Life Sci  2018,61(10),1191-1204","journal-title":"Sci China Life Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"106324","DOI":"10.1016\/j.ejps.2022.106324","volume":"181","author":"Vemula D.","year":"2023","unstructured":"Vemula D.; Jayasurya P.; Sushmitha V.; Kumar Y.N.; Bhandari V.; CADD, AI and ML in drug discovery: A comprehensive review. Eur J Pharm Sci  2023,181,106324","journal-title":"Eur J Pharm Sci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.2174\/0929867043364531","volume":"11","author":"Meresse P.","year":"2004","unstructured":"Meresse P.; Dechaux E.; Monneret C.; Bertounesque E.; Etoposide: discovery and medicinal chemistry. Curr Med Chem  2004,11(18),2443-2466","journal-title":"Curr Med Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1021\/ci990307l","volume":"39","author":"Wildman S.A.","year":"1999","unstructured":"Wildman S.A.; Crippen G.M.; Prediction of physicochemical parameters by atomic contributions. J Chem Inf Comput Sci  1999,39(5),868-873","journal-title":"J Chem Inf Comput Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jpba.2008.03.023","volume":"47","author":"Ma C.Y.","year":"2008","unstructured":"Ma C.Y.; Yang S.Y.; Zhang H.; Xiang M.L.; Huang Q.; Wei Y.Q.; Prediction models of human plasma protein binding rate and oral bioavailability derived by using GA\u2013CG\u2013SVM method. J Pharm Biomed Anal  2008,47(4-5),677-682","journal-title":"J Pharm Biomed Anal"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nchem.1243","volume":"4","author":"Bickerton G. R.","year":"2012","unstructured":"Bickerton G. R.; Paolini G. v.; Besnard J.; Muresan S.; Hopkins A. L.; Quantifying the chemical beauty of drugs. Nat Chem  2012,4(2),90-98","journal-title":"Nat Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1021\/ci960113v","volume":"37","author":"Estrada E.","year":"1997","unstructured":"Estrada E.; Spectral Moments of the Edge-Adjacency Matrix of Molecular Graphs. 2. Molecules Containing Heteroatoms and QSAR Applications. J Chem Inf Comput Sci  1997,37(2),320-328","journal-title":"J Chem Inf Comput Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"101828","DOI":"10.1016\/j.rechem.2024.101828","volume":"11","author":"Szostek T.","year":"2024","unstructured":"Szostek T.; Otto-\u015alusarczyk D.; Roszkowski P.; Struga M.; Szulczyk D.; Exploring the bioactive potential of (2-imino-4-oxo-1,3-thiazolidin-5-yl)acetic acid derivatives: A comprehensive review. Results Chem  2024,11,101828","journal-title":"Results Chem"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673400295250913044755","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/245999\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673400295250913044755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:03:41Z","timestamp":1790913821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/245999\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":74,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673400295250913044755","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}